logo
  

Genentech : Alzheimer's Prevention Initiative Study Of Crenezumab Didn't Show Clinical Benefit

Genentech, in its update on alzheimer's prevention initiative study evaluating crenezumab in autosomal dominant alzheimer's disease, said Thursday that the investigational medicine did not slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer's disease.

"We're disappointed that the treatment did not demonstrate a statistically significant clinical benefit," said Eric Reiman, Banner Alzheimer's Institute executive director and one of the study leaders.

Roche Group's (RHHBY) Genentech noted that the trial did not demonstrate a statistically significant clinical benefit in either of its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function, measured by the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) composite cognitive score and the Free and Cued Selective Reminding Test Cueing Index, respectively.

According to the company, small numerical differences favoring crenezumab were observed across the co-primary and multiple secondary and exploratory endpoints, but those were not statistically significant. No new safety issues were identified with crenezumab during the study. Further analyses of data are ongoing.

The company will present initial data at the Alzheimer's Association International Conference on August 2, 2022.

The trial enrolled 252 people who are members of the world's largest extended family with ADAD in Colombia, with 94% of participants completing the study. Two-thirds of participants carried the Presenilin 1 E280A mutation which typically causes cognitive impairment due to Alzheimer's disease around age 44. Participants were randomized to receive crenezumab, an investigational treatment discovered by AC Immune SA, or placebo over five to eight years.

Genentech stated that it is also evaluating the potential of gantenerumab in autosomal dominant Alzheimer's disease, as well as for the prevention of sporadic Alzheimer's and treatment of early Alzheimer's in late stage clinical trials. Results from the phase III GRADUATE studies of gantenerumab in early Alzheimer's are expected in the fourth quarter of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fifth Season is recalling a limited amount of its branded Crunchy Sesame Salad Kits due to undeclared milk and egg, known allergens, the U.S. Food and Drug Administration said. The recall involves Fifth Season branded Crunchy Sesame Salad Kit with UPC Code: 52070008147 and Best By Date of 16-AUG-2022 and 15-AUG-2022. Luxury electric car maker Tesla Inc. has produced more than 3 million vehicles, of which 1 million in Shanghai Gigafactory, according to its founder and Chief Executive Officer Elon Musk. In a tweet on Sunday, Musk said, "Congrats Giga Shanghai on making millionth car! Total Teslas made now over 3M." King's Hawaiian is recalling its Pretzel Slider Buns, Pretzel Hamburger Buns and Pretzel Bites products as they contain one ingredient already recalled by Lyons Magnus, the U.S. Food And Drug Administration said. The Pretzel recall was initiated out of an abundance of caution after one of its supplier Lyons Magnus recently called back various nutritional and beverage products.
Follow RTT